Maozhou Yang

Maozhou Yang

Auto-generated profile, based on publicly available information

Maozhou Yang

Quanticision Diagnostics, Inc, RTP, NC 27709, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JZJiandi Zhang
Jiandi Zhang
MYMaozhou Yang
Maozhou Yang
The commentary by Nielsen et al. ( 1) summarized over a decade of efforts by a group of dedicated oncologists (the International Ki67 in breast cancer Working Group [IKWG]) attempting to standardize immunohistochemistry (IHC)–based Ki67 assessment in daily clinical practice. A key recommendation in the commentary is that “in this T1-2, N0-1 patient group, the IKWG consensus is that Ki67 5% or less, or 30% or more, can be used to estimate prognosis.”


1 January 2021 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
LXLei Xin
Lei Xin
FTFangrong Tang
Fangrong Tang
BSBo Song
Bo Song
MYMaozhou Yang
Maozhou Yang
JZJiandi Zhang
Jiandi Zhang
Xin L, et al. J Gastric Cancer. 2021 Dec;21(4):335-351. https://doi.org/10.5230/jgc.2021.21.e32

1 July 2020 in Future Oncology
Verified
Journal Article
Closed access
JZJiandi Zhang
Jiandi Zhang
MYMaozhou Yang
Maozhou Yang
Over a century of clinical practice has led to the accumulation of millions of archived formalin fixed paraffin embedded (FFPE) cancer specimens with detailed medical records worldwide. Absolute quantitation of clinical protein biomarkers in these FFPE specimens allows individual specimens to be profiled at the population level, with the absolute nature of the measurements enabling the continuous processing of archived FFPE specimens over the time. A continuously growing cancer patient profile database is proposed here to support "big data" profiling of these protein biomarkers alone or in combination, enabling next-generation retrospective-prospective analytics into the field of clinical diagnostics.

15 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
LXLei Xin
Lei Xin
FTFangrong Tang
Fangrong Tang
BSBo Song
Bo Song
MYMaozhou Yang
Maozhou Yang
JZJiandi Zhang
Jiandi Zhang
Background One causing factor underlying failures of several clinical trials of anti-EGFR therapies is the lack of effective method to select patients overexpressing EGFR protein. Quantitative Dot Blot method (QDB) is proposed here to measure EGFR protein levels objectively and quantitatively. Its feasibility was evaluated for prognosis of overall survival (OS) of gastric cancer patients. Methods Formalin Fixed Paraffin Embedded (FFPE) slices of 2×5 μm from gastric and Lung cancer specimens were used to extract total tissue lysate for QDB measurement. Absolutely quantitated EGFR protein levels were used for Kaplan-Meier Overall Survival (OS) analysis of gastric cancer patients. Results EGFR protein levels ranged from 0 to 772 pmole/g (n=246) for gastric, and from 0 to 2695 pmole/g (n=81) for lung cancer patients. Poor correlation was observed between quantitated EGFR levels and immunohistochemistry (IHC) scores with r=0.018, p=0.786 from Spearman’s correlation analysis. EGFR was identified as an independent negative prognostic biomarker for gastric patients only through absolute quantitation, with HR at 2.29 (95%CI:1.23-4.26, p=0.0089) from multivariate cox regression OS analysis. A cutoff of 207.7 pmole/g was proposed to stratify gastric cancer patients, with 5-year survival probability at 37% for those whose EGFR levels were above the cutoff, and at 64% those below the cutoff based on Kaplan-Meier OS analysis. p=0.0057 from Log Rank test. Conclusion A QDB-based assay was developed for both gastric and Lung cancer specimens to measure EGFR protein levels absolutely, quantitatively and objectively. This assay should facilitate clinical trials aiming to evaluate anti-EGFR therapies retrospectively and prospectively.